PANCREATIC DUCTAL ADENOCARCINOMA

This trial compares two types of surgery for pancreatic cancer in the body or tail of the pancreas: minimally invasive (laparoscopic or robot-assisted) versus traditional open surgery. The goal is to see if the less invasive approach can remove the tumor just as completely. Adult…

This early-phase trial tested a new drug called RO7496353 combined with an immunotherapy (atezolizumab) and sometimes chemotherapy in 102 people with advanced lung, stomach, or pancreatic cancer. The main goal was to check safety and side effects. Researchers also looked at how t…

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…

This completed phase 1/2 trial tested an experimental drug called Y101D combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for 71 people with advanced pancreatic cancer. The goal was to find a safe dose and see if the combo helps shrink tumo…

This early-phase trial tested whether adding a new drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe and could help shrink tumors in people with locally advanced pancreatic cancer that cannot be removed by surgery. 43 participants received the combination. The main…

This study tested a combination of three drugs (nivolumab, BMS-813160, and GVAX) in 22 people with locally advanced pancreatic cancer who had already received chemotherapy and radiation. The goal was to see if the treatment was safe and could help the immune system better attack …

This study tested a combination of three chemotherapy drugs (paclitaxel protein bound, gemcitabine, and cisplatin) in 34 people with metastatic pancreatic cancer that had not been treated before. If the cancer got worse, a fourth drug (paricalcitol) was added. The goal was to see…

This phase II trial tested a combination of three chemotherapy drugs (nab-paclitaxel, cisplatin, and gemcitabine) in 42 people with metastatic pancreatic cancer that had not been treated before. The main goal was to see how many patients were alive after 12 months. The study also…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This large phase III trial tested whether adding the targeted drug erlotinib or chemoradiation to standard chemotherapy after surgery could help people with pancreatic cancer live longer. Over 500 patients who had their tumor removed were randomly assigned to different treatment …

This study tested a modified cold virus called LOAd703 in 51 people with pancreatic cancer. The virus is designed to infect and kill cancer cells while also boosting the immune system. It was given alongside standard chemotherapy, and in some cases an immunotherapy drug, to see i…

This phase 2 trial tested two standard chemotherapy regimens, Folfirinox and Gemcitabine/nab-paclitaxel, in 150 patients with untreated metastatic pancreatic cancer. The goal was to see which works better and to use lab tests to personalize treatment. The study is complete, and r…

This completed phase 2 trial tested whether adding an anti-PD-1 immunotherapy drug to standard chemotherapy (modified-FOLFIRINOX) helps patients with locally advanced or borderline resectable pancreatic cancer. The study enrolled 392 participants and compared the combination agai…

This study tested whether adding two immunotherapy drugs (pembrolizumab and defactinib) to standard chemotherapy before and after surgery could help the body fight pancreatic cancer better. It involved 28 people with early-stage, removable pancreatic cancer. The goal was to see i…

This study tested a combination of two drugs, pembrolizumab (an immunotherapy) and azacitidine (a drug that affects gene activity), in people with advanced pancreatic cancer that had worsened after initial treatment. The goal was to see if this combination could help control the …

This phase 2 trial tested a new drug called onvansertib combined with standard chemotherapy for people with metastatic pancreatic cancer that had already been treated once. The study enrolled 41 adults and measured how many patients' tumors shrank. The goal is to find a better se…

This study tested a new treatment plan for people with advanced pancreatic cancer that has spread. It combined chemotherapy with drugs that change how genes work and boost the immune system. The goal was to see if this approach is safe and can help control the disease. 75 patient…

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…

This phase 1 trial tested a new radioactive imaging agent called 64Cu-DOTA-ECL1i to see if it can detect a protein called CCR2 in pancreatic tumors using PET scans. The study involved 69 adults with pancreatic ductal adenocarcinoma at various stages. The goal was to see if the sc…

This study tested a new radioactive tracer called [18F]FAPI-74 for PET scans in people with gastrointestinal cancers, including liver, bile duct, stomach, pancreatic, and colorectal cancers. The goal was to see if the tracer can accurately detect cancer cells by comparing scan re…

This study tested whether it is safe and possible to collect a blood sample from the portal vein (a major liver blood vessel) during a routine endoscopic ultrasound in 23 people with pancreatic cancer. The goal was to find and count circulating tumor cells (cancer cells in the bl…

This study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue r…

This study looked at whether it is safe and possible to grow mini-tumors (organoids) from pancreatic cancer samples in the lab. 60 patients with pancreatic cancer provided tumor tissue during surgery or biopsy. The goal was to see if these organoids could be used to test differen…

This study looked at 200 patients with early-stage pancreatic cancer who had Whipple surgery. Researchers found that some patients developed fatty liver within six months after surgery, which may affect nutrition, blood sugar control, and long-term survival. The goal is to help d…